Company / Operating Cash Flow
Kymera Therapeutics, Inc. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$232.9M
FY2025
5-year range
-$232.9M / $17.9M
FY2021-FY2025
Trend
-19.7%
vs FY2024
Sector context
#178 of 216
Health Care
What the data says
Kymera Therapeutics, Inc.'s operating cash flow of -$233M is lower than 82% of companies in the Health Care sector (FY2025). Declined from -$103M to -$233M over the past 2 years.
Based on SEC 10-K filings.
-$233M in FY2025.
Declined from -$103M to -$233M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 216This company -$232.9M Sector average $659.0M
▼
-135.3% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 19.7% year-over-year.
- Ranks #178 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$232.9M | -19.7% |
| FY2024 | -$194.5M | -89.2% |
| FY2023 | -$102.8M | +32.8% |
| FY2022 | -$153.1M | -955.0% |
| FY2021 | $17.9M | +0.0% |
| FY2020 | $17.9M | +0.0% |
| FY2019 | $17.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026